Indeed, “classical” anti-histamines targeting H1R failed to be effective as “add-on” therapy in eczema (Matterne et al., 2019), although recently, promising results were published with H4R antagonists (Werfel et al., 2019) and combination of H1R and H4R antagonists (Köchling et al., 2017). This evidence concerns the gene HRH4 and Eczematoid dermatitis.